Attached files
| file | filename |
|---|---|
| EX-10.12 - EX-10.12 - Taysha Gene Therapies, Inc. | d938924dex1012.htm |
| EX-10.11 - EX-10.11 - Taysha Gene Therapies, Inc. | d938924dex1011.htm |
| EX-10.10 - EX-10.10 - Taysha Gene Therapies, Inc. | d938924dex1010.htm |
| EX-10.8 - EX-10.8 - Taysha Gene Therapies, Inc. | d938924dex108.htm |
| EX-10.7 - EX-10.7 - Taysha Gene Therapies, Inc. | d938924dex107.htm |
| EX-10.6 - EX-10.6 - Taysha Gene Therapies, Inc. | d938924dex106.htm |
| EX-10.5 - EX-10.5 - Taysha Gene Therapies, Inc. | d938924dex105.htm |
| EX-5.1 - EX-5.1 - Taysha Gene Therapies, Inc. | d938924dex51.htm |
| EX-3.4 - EX-3.4 - Taysha Gene Therapies, Inc. | d938924dex34.htm |
| EX-3.3 - EX-3.3 - Taysha Gene Therapies, Inc. | d938924dex33.htm |
| EX-3.1 - EX-3.1 - Taysha Gene Therapies, Inc. | d938924dex31.htm |
| EX-1.1 - EX-1.1 - Taysha Gene Therapies, Inc. | d938924dex11.htm |
| S-1/A - S-1/A - Taysha Gene Therapies, Inc. | d938924ds1a.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Registration Statement No. 333-248559 on Form S-1 of our report dated July 31, 2020 (September 17, 2020 as to the effects of the stock split described in Note 9), relating to the financial statements of Taysha Gene Therapies, Inc. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ Deloitte & Touche LLP
Dallas, Texas
September 17, 2020